

Supplementary Information

Table S1. Primers used in this study.

Primer	Sequence (5'-3')
IL8-F	AGAGACAGCAGAGCACAC
IL8-R	AGTTCTTTAGCACTCCTTGG
AREG-F	TCCACTCGCTCTTCCAACAC
AREG-R	ATGGTTCACGCTTCCCAGAG
CXCL1-F	GCAGGGAATTCACCCAAGA
CXCL1-R	CTTCAGGAACAGCCACCAGT
DUSP1-F	ACAAGGCAGACATCAGCTCC
DUSP1-R	TCGCCTCTGCTTCACAACT
EGFR-F	GTGTGATCCAAGCTGTCCA
EGFR-R	CTGTATTTGCCCTCGGGGT
TLR2-F	GTACCTGTGGGGCTCATTGT
TLR2-R	CAAGACCCACACCATCCACA
SIRT1-F	TCGCCTTGCTGTAGACTTCC
SIRT1-R	TTTGGATTCCCACAACCTGT
GAPDH-F	GAAGGTGAAGGTCGGAGTC
GAPDH-R	(5'-GAAGATGGTGATGGGATTTC

Table S2. siRNAs used in this study.

Gene	siRNA reference	Sequence (5'-3')
EGFR	SI02660140 (a)	TACGAATATTAACACTTCAA
	SI02660147 (b)	ATAGGTATTGGTGAATTTAAA
TLR2	SI00050015 (a)	CTGGGCAGTCTTGAACATTTA
	SI00050022 (b)	CAGGTAAAGTGGAAACGTTAA
SIRT1	SI00098434 (a)	CAAGCGATGTTTGATATTGAA
	SI00098441 (b)	CAGGATTATTGTATTTACGTT
	Control AllStars	UUCUUCGAACGUGUCACG




Figure S1. Effect of a panel of molecules on NTHi viability. Bacteria were collected from a freshly grown chocolate agar plate with 1 ml PBS, and adjusted to OD₆₀₀=1; 100 μ l of this suspension (\sim 10⁸ c.f.u.) were incubated in 1 ml EBSS medium for 2 h in the presence of Ro31-8220 1 μ M, SB202190 30 μ M, PD98059 50 μ M, SP600125 50 μ M, DEX 1 μ M, FP 1 μ M, CAPE 52.8 μ M, BAY11-7093 5 μ M, EGF 167 nM, TAPI-2 100 μ M, GM6001 200 μ M, RESV 20 μ M, TEOPH 20 μ M, FLUV 200 μ M, SALM 1 μ M, FORM 10 μ M, PROP 20 μ M, db-cAMP 1 mM, IBMX 1mM, ROFLUM 1 μ M, ROLIP 10 μ M, 8-pCPT-2'-O-Me-cAMP 100 μ M, PKI 1 μ M, or vehicle solution (control non-treated, CON). Bacterial viability was assessed by serial dilution and plating. Data are shown as per cent viability compared with CON non-treated bacteria considered to be 100%, given that vehicle solutions used in this study did not alter bacterial viability (data not shown). Data are the means of three independent experiments performed at least in triplicate. *p<0.05 compared to bacterial viability in the absence of treatment. CAPE, BAY11-7083 and resveratrol displayed a bactericidal effect.




Figure S2. Networks of interactions between the selected genes obtained using IPA. (A) Network 1 (best scored network). (B) Network 3. (C) Network 8. (D) Network 21.




Figure S3. Relative comparison between gene expression in NTHi375-infected and control (CON) uninfected A549 cells. IL-8, AREG, CXCL-1 and DUSP1 mRNA levels, assessed by RT-qPCR in A549 control cells (CON) or cells infected with NTHi375 for 2 h (data are mean±SD; n=9). IL-8, AREG, CXCL-1 and DUSP1 mRNA levels were higher in NTHi375 infected- than in uninfected cells (IL-8, $p < 0.05$; AREG, $p < 0.05$; CXCL-1, $p < 0.001$; DUSP1 $p < 0.05$). Data are shown as gene expression in infected- compared to control uninfected cells.




Figure S4. Validation of siRNA-mediated knockdown of TLR2, EGFR and SIRT1. TLR2, EGFR and SIRT1 mRNA levels were measured by RT-qPCR on control (AS-CON) and siRNA treated cells. In all cases, a reduction of ~50-80% was observed in siRNA-treated compared to control (AS-CON) cells.




Figure S5. Effect of a panel of host-directed drugs on NTHi375 adhesion to A549 epithelial cells. Effect of cell treatment with TAPI-2 100 μ M and GM6001 200 μ M (A); RESV 20 μ M and TEOPH 20 μ M (B); SALM 1 μ M and FORM 10 μ M (C); db-cAMP 1 mM, IBMX 1mM, ROFLUM 1 μ M, ROLIP 10 μ M, 8-pCPT-2'-O-Me-cAMP 100 μ M and PKI 1 μ M (D) on NTHi375 adhesion to A549 cells. In all cases, comparable NTHi375 adhesion to treated- and control (CON) untreated cells was observed.